Ann: CardieX Corporate Update Webinar, page-7

I just listened to the webinar and was extremely impressed with the commitment of C2 Ventures and it was good to get the technical update from Catherine, who adds great credibility on the technical presentation side. I like the mix of Craig, Neil and Catherine.I also liked the information that a chief medical officer will soon be joining CDX, who comes from the FDA clinical department. I see FDA clearances as ongoing major value add milestones so this appointment to me is very good news, plus also validation of our technology that this person sees the potential in CDX. I have lost a considerable sum of money on my CDX investment at current prices but will be taking up my full allocation plus some topup. I recall Neil saying the market cap for the company at 8c price is approx 23 million with CDX having 11 million in cash! This gives a ridiculously low valuation for CDX considering its currently cleared products, technology pipeline and the medical acceptance of the technology. I now feel confident CDX will have the cash to execute. Good luck to all longterm inv